Screening campaigns return long hit lists thick with artifacts and dead-end chemistry, and triaging them by hand is slow and expertise-heavy.
High-throughput and virtual screening can return large hit lists, but many hits are assay artifacts, promiscuous binders, or chemically intractable series that waste follow-up effort. Separating genuine, developable starting points from noise is slow and expertise-heavy. AI approaches help prioritize hits, flag likely artifacts, and predict which series are worth pursuing so chemists spend follow-up capacity where it counts.
How AI helps triage and prioritize screening hits
Hit-triage tools apply predictive models to a raw hit list to estimate which compounds are real, tractable starting points and which are likely dead ends. They flag structural patterns associated with assay interference and promiscuous, non-specific binding, predict properties that bear on developability, and can cluster hits into chemical series so a team sees coherent starting points rather than thousands of individual rows. In virtual screening, learned scoring functions help rank docked or generated compounds more reliably than a single physics score alone. The goal is to focus expert attention, not replace it. These models propose which hits and series deserve follow-up; chemists confirm the assays, inspect the chemistry, and decide what to progress. A flag for likely interference is a prompt to check, not a verdict, and the bench remains the arbiter of whether a hit is genuine.
What to evaluate before buying hit-triage AI
The key question is whether the models generalize to your assays and chemistry. Interference and promiscuity models trained on particular assay types or compound sets may transfer poorly, so ask how a tool was validated and how it performs on chemistry like yours, and prefer models that flag with explanations a chemist can inspect over opaque scores. Confidence estimates matter, because a triage tool that hides its uncertainty can quietly discard good chemistry. Also consider how the tool ingests your screening output and assay context, whether it can incorporate your own confirmatory results to improve over time, and how it balances removing artifacts against the risk of filtering out unusual but valuable series.
How teams typically get started
A low-risk entry point is running the tool on a completed screening campaign where you already know which hits progressed and which proved to be artifacts. Comparing its prioritization against that known outcome shows whether it would have saved follow-up effort and, just as important, whether it would have discarded any hit that later mattered — all before it influences a live campaign.
AI Use Cases That Address This Problem
Hit Identification & Lead Optimization
Frequently asked questions
Why do screening campaigns produce so many low-quality hits?
High-throughput and virtual screening test very large compound sets, and many apparent hits are assay artifacts, compounds that interfere with the readout, or promiscuous binders that hit many targets non-specifically. Others belong to chemically intractable series. Separating genuine, developable hits from this noise is a well-known bottleneck in early discovery.
How does AI help prioritize screening hits?
By scoring a hit list with models that flag likely artifacts and promiscuous binders, predict developability-relevant properties, and cluster compounds into coherent chemical series. The result is a prioritized view that helps chemists decide where to spend follow-up effort — the tool suggests, and the team confirms at the bench.
Could hit-triage AI discard good compounds?
Yes, that is the main risk. A model that aggressively filters can remove unusual but valuable chemistry along with the noise, so triage should inform decisions rather than make them automatically. Look for tools that explain their flags and report confidence, and keep a chemist in the loop on what gets deprioritized.
What should we ask a hit-triage vendor?
Ask how the models were trained and validated, how they perform on your assay types and chemical space, whether flags come with inspectable explanations and confidence estimates, and whether the tool can learn from your confirmatory results. A retrospective test on a completed campaign is a strong way to check its value.
Eli Lilly collaboration worth up to $670 million to discover novel therapies
Genesis Therapeutics (now Genesis Molecular AI) entered a strategic collaboration with Eli Lilly to discover novel therapies for up to five targets across a range of therapeutic areas using its Genesis Molecular AI drug-discovery platform, receiving $20 million upfront with a potential total value of up to $670 million.
Nimbus TYK2 program (TAK-279) acquired by Takeda for $4 billion upfront
A selective TYK2 inhibitor discovered using Schrödinger's physics-based computational platform (developed by Nimbus Therapeutics) was acquired by Takeda for $4 billion upfront, demonstrating commercial validation of a computationally designed clinical asset.
Eli Lilly AI and robotics drug-discovery collaboration
XtalPi and Eli Lilly announced a collaboration to apply XtalPi's AI and robotics-driven drug discovery platform to uncover first-in-class small-molecule therapeutics.
Cube Biotech collaboration to design novel Amylin Receptor agonists
Iktos and Cube Biotech announced a strategic collaboration to discover novel small-molecule agonists of the Amylin Receptor, pairing Iktos's AI-driven generative design platform with Cube Biotech's membrane protein production and purification technologies.
Pfizer collaboration expanded for next-generation molecular modeling
XtalPi announced an expansion of its research collaboration with Pfizer to build a next-generation molecular modeling platform for drug discovery, applying XtalPi's AI and robotics capabilities to improve the accuracy of computational predictions.
Pierre Fabre Laboratories oncology drug-discovery collaboration
Pierre Fabre Laboratories and Iktos announced an integrated drug-discovery collaboration to identify and develop novel small-molecule candidates in oncology, with Iktos applying its AI-driven generative design platform alongside Pierre Fabre's medicinal chemistry, biology, and preclinical development.